If you think you’ve noticed a spike in biotech venture capital dealmaking, you’re not seeing things. Activity in one of venture capital’s riskiest segments has been on a marked rise. Over the last year, venture capitalists gave a total $5.65 billion to finance startup drugmakers, according to the VC Deal data- base — 22% more than the $4.63 billion stumped up in the same period a year earlier. Average deal size was up by 8.5%, and VCs spread their money to more companies — 366 firms as opposed to the 325 enterprises a year earlier.
